Epratuzumab Y-90

N/A

Report date: 2025/09/11 11:16:14

Base Information

Drug NameEpratuzumab Y-90
Drug Alias NameAnti-CD22 monoclonal antibody LL2-Y-9090Y-hLL2 IgGYttrium-90 epratuzumab tetraxetanMonoclonal antibody LL2-Y-90Y-90 epratuzumab tetraxetan +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Yttrium > 90YRadiation-emitting products > Radioactive therapeutic agent +[4] 
Mechanisms of ActionIonising radiation emittersCD22 modulators
TargetsCD22
Therapy Area/IndicationsPain, PostoperativeLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunomedics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences IncNantes University Hospital
Active IndicationsN/A
Inactive IndicationsPain, PostoperativeLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG